8IRR image
Deposition Date 2023-03-19
Release Date 2023-06-21
Last Version Date 2024-11-13
Entry Detail
PDB ID:
8IRR
Title:
Dopamine Receptor D1R-Gs-Rotigotine complex
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Lama glama (Taxon ID: 9844)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.20 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
Chain IDs:A
Chain Length:246
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene (Uniprot):GNB1
Chain IDs:B
Chain Length:353
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Gene (Uniprot):GNG2
Chain IDs:C (auth: G)
Chain Length:67
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nanoboy 35
Chain IDs:D (auth: N)
Chain Length:135
Number of Molecules:1
Biological Source:Lama glama
Polymer Type:polypeptide(L)
Molecule:D(1A) dopamine receptor
Gene (Uniprot):DRD1
Chain IDs:E (auth: R)
Chain Length:502
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural genomics of the human dopamine receptor system.
Cell Res. 33 604 616 (2023)
PMID: 37221270 DOI: 10.1038/s41422-023-00808-0

Abstact

The dopaminergic system, including five dopamine receptors (D1R to D5R), plays essential roles in the central nervous system (CNS); and ligands that activate dopamine receptors have been used to treat many neuropsychiatric disorders, including Parkinson's Disease (PD) and schizophrenia. Here, we report cryo-EM structures of all five subtypes of human dopamine receptors in complex with G protein and bound to the pan-agonist, rotigotine, which is used to treat PD and restless legs syndrome. The structures reveal the basis of rotigotine recognition in different dopamine receptors. Structural analysis together with functional assays illuminate determinants of ligand polypharmacology and selectivity. The structures also uncover the mechanisms of dopamine receptor activation, unique structural features among the five receptor subtypes, and the basis of G protein coupling specificity. Our work provides a comprehensive set of structural templates for the rational design of specific ligands to treat CNS diseases targeting the dopaminergic system.

Legend

Protein

Chemical

Disease

Primary Citation of related structures